Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1 domain family member 3 pseudogene 3 (TBC1D3P3, ENSG00000278160) is a human pseudogene classified by HGNC as non-protein-coding[3]. Pseudogenes are genomic DNA sequences similar to functional genes but typically lack protein-coding potential due to mutations or lack of expression[3]. TBC1D3P3 shows sequence similarity to the TBC1D3 gene family, which in functional members is involved in GTPase signaling and vesicle trafficking[2]. However, as a pseudogene, TBC1D3P3 is not believed to encode a functional protein or possess recognized biological functions, disease roles, or clinical relevance as a therapeutic target[3][1]. The Ensembl gene ID ENSG00000278160 matches TBC1D3P3, confirmed as a pseudogene by academic and commercial databases[3][1]. Pseudogenes like TBC1D3P3 may impact genomic regulation or expression patterns, but do not act as receptors, enzymes, or direct therapeutic targets[1][3]. No evidence links TBC1D3P3 to disease, drug interaction, or molecular function as with other TBC1D3 gene family members[3][1]. By convention, pseudogene entries are not considered therapeutic targets and have limited direct biomedical application. TBC1D3P3 is a pseudogene, not a protein or receptor, and thus not a drug target[3][1]. There is no evidence of disease or drug associations. The entry is accurate in nomenclature, but as a pseudogene, it does not meet the criteria for a therapeutic target. If you intended a protein-coding gene from the TBC1D3 family (such as TBC1D3B), those have function as GTPase-activating proteins for RAB GTPases and potential disease associations[2], but the specific queried pseudogene (ENSG00000278160, TBC1D3P3) lacks such attributes[3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC domain family member 3 pseudogene 3 (TBC1D3P3).